EULAR 2022 | BE MOBILE 1 and 2: How might bimekizumab impact axSpA clinical practice? | rheumatology.medicinematters.com

Register Login

Medicine Matters Rheumatology

JAVASCRIPT NEEDED

Please enable JavaScript on your browser, so that you can use all features of this website.

window.dataLayer = window.dataLayer || []; window.dataLayer.push({ 'event': 'track', 'eventCategory': 'flash_warning', 'eventAction': 'Javascript needed', 'eventLabel': 'Please enable JavaScript on your browser, so that you can use all features of this website.' });

20-06-2022 | EULAR 2022 | Conference coverage | Video

BE MOBILE 1 and 2: How might bimekizumab impact axSpA clinical practice?

Fabian Proft discusses the potential impact of bimekizumab on the treatment of radiographic and nonradiographic axial spondyloarthritis in light of findings from the BE MOBILE 1 and 2 trials (3:02).

Related content

25-05-2022 | Bimekizumab | Feature | Article

A quick guide to the phase 3 trials of bimekizumab in spondyloarthritis

01-06-2022 | EULAR 2022 | Conference coverage | News

BE MOBILE trials support bimekizumab for the treatment of axSpA

14-06-2022 | EULAR 2022 | Conference coverage | Video

The BE MOBILE 1 and 2 trials of bimekizumab in axSpA

04-06-2022 | EULAR 2022 | Conference coverage | News

Bimekizumab beneficial for psoriatic arthritis in phase 3 trials

Version: 0.2002.0